Mologen (DE:MGNG) is developing novel immunotherapies for use in the post-chemo maintenance setting in cancer and for the treatment of infectious diseases. Lead candidate MGN1703 is in three clinical trials for different indications, including a pivotal Phase III study, IMPALA, in metastatic colorectal cancer (mCRC) with data due in H118. Meanwhile, initial data from the Phase II IMPULSE study in lung cancer in H117 could positively affect partnering or financing options. We value Mologen at €387m, or €17 per share.
MGN1703: An innovative immunotherapy
MGN1703, an innovative TLR9 agonist, is in two clinical trials aiming to show that a switch maintenance therapy with an active immunotherapy leads to increased overall survival (OS) in patients who have responded to initial chemo. Preliminary OS data from the Phase IIa IMPACT study in mCRC are encouraging, with the benefit more pronounced in patients who responded to induction chemo. This underscores the designs of IMPALA and IMPULSE, which only include chemoresponders. The TEACH study in HIV is the first non-cancer study for MGN1703.
To Read the Entire Report Please Click on the pdf File Below